Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

2.690 -0.100 (-3.58%)

Delayed Quote Updated: 2:32 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Niagen Bioscience, Inc. - Common Stock

< Previous 1 2 3 Next >

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 06, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's after-hours session. ↗

August 06, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

August 06, 2025

From Niagen Bioscience, Inc.

Via Business Wire

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

What's Next: Niagen Bioscience's Earnings Preview ↗

May 06, 2025

Via Benzinga

Examining the Future: Niagen Bioscience's Earnings Outlook ↗

August 05, 2025

Via Benzinga

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference

August 04, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

July 23, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

July 14, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

July 08, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

June 20, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Participate in the BIO 2025 International Convention

June 11, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

June 09, 2025

From Niagen Bioscience, Inc

Via Business Wire

What 4 Analyst Ratings Have To Say About Niagen Bioscience ↗

June 06, 2025

Via Benzinga

Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference

June 04, 2025

From Niagen Bioscience, Inc

Via Business Wire

This Sandisk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

May 27, 2025

Via Benzinga

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

May 07, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

April 29, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

May 05, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

April 28, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

April 07, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

March 20, 2025

From Niagen Bioscience, Inc

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.